CNTB Connect Biopharma Holdings Ltd Insider Trading

Director James Huang buys 150,000 shares of CNTB at $2.48; stock now $2.15, down -43.7% from 52-week high amid revenue collapse of -99.8%.

James Huang (Director) purchased 150,000 shares at $2.48 on 2026-05-29, increasing his holdings from 13,160,000 to 13,310,000 shares. The stock has since declined to $2.15 (current price), representing a -13.0% drop over the past 30 days and -17.0% over 90 days. Most notably, the company's fundamentals are severely deteriorated: annual revenue growth stands at -99.8%, quarterly revenue is just $169,000.00, and the company posted a net loss of $-19,398,000.00 in its latest full fiscal year. Huang's prior buy at this ticker on 2026-03-31 produced 90-day returns of -32.2%, and across his broader cross-ticker track record (1 prior buy), his average 90-day return is -32.2% with a 0.00% win rate. This new purchase occurs against ongoing deterioration in both stock price and fundamental metrics.

Director Huang James buys 1,160,000 shares of CNTB at $3.45 for $4,002,000, raising stake to 13,160,000 shares amid severe revenue collapse (-99.8%) and ongoing losses ($-17.2M).

Director Huang James purchased 1,160,000 shares at $3.45 on 2026-03-31, increasing his holdings by 9.7% to 13,160,000 shares. This $4,002,000 acquisition occurred when the stock trades at $2.72 (26.3% below its 52-week high of $3.69), suggesting the purchase price was above current levels. The company faces severe operational stress: latest quarterly revenue stood at $16,000, representing a -99.8% annual revenue decline, with net losses of $-17.2M over the most recent full fiscal year. An insider director acquiring a material stake while the company experiences near-complete revenue collapse and substantial ongoing losses is noteworthy and merits scrutiny of the underlying business dynamics and recovery thesis.